Lisheng Pharmaceutical announced that in order to further optimize resource allocation, taking into account asset evaluation results and market conditions, it plans to publicly list and transfer 24.65% of its shares at a reserve price of not less than 120.292,000 yuan. After the transaction is completed, the company will no longer hold shares in Tanabe Pharmaceutical. According to the “Administrative Measures on Major Asset Reorganization of Listed Companies”, this transaction does not constitute a major asset restructuring. The matter was publicly listed and transferred at the Tianjin Property Exchange Center after approval by the company's shareholders' meeting and relevant authorities.